Karolinska Development :: View by company A-Z

Karolinska Development

Aprea AB Aprea is developing pharmaceuticals that reactivate the p53 protein, which is damaged in many types of cancer. www.aprea.com		Athera Biotechnologies AB Athera develops products for the risk assessment and treatment of cardiovascular disease related to inflammatory and immunological mechanisms. www.athera.se		Axelar AB Axelar is developing a cancer drug that inhibits the Insulin-like Growth Factor 1 receptor (IGF-1). www.axelar.se
BioChromix AB BioChromix is developing diagnostic tests and R&D assays for Alzheimer’s disease, with the aim to commercialize at or prior to Phase II clinical trials, through a strategic partnership or licensing of the project. www.biochromix.com		BioChromix Pharma AB BioChromix Pharma develops new drugs for the treatment of neurodegenerative diseases, such as Alzheimer’s. www.biochromixpharma.com		Biosergen AS Biosergen develops new antibiotics for the treatment of fungal diseases. www.biosergen.com
Clanotech AB Clanotech is developing small molecules for alpha5beta1-integrin inhibition for treatment of diseases of the eye. www.clanotech.se		Dilafor AB Dilafor is developing pharmaceuticals against protracted labor based on modified heparin. www.dilafor.com		Dilaforette AB Severe malaria kills one million people every year, mostly children. Dilaforette is developing a heparin analogue, sevuparin, for the treatment of severe malaria that prevents infected cells’ ability to block blood vessels.
Inhalation Sciences Sweden AB Inhalation Sciences Sweden has developed a research platform that can provide early stage pharmacokinetic and dynamic data for very early selection of drug candidates. www.inhalation.se		KDev Oncology AB GliGene is developing antagonists to the Hedgehog pathway for the treatment of solid tumors.		KDev Oncology AB Akinion Pharmaceuticals is developing FLT-3 kinase inhibitors for cancer treatment. www.akinion.com
Lipidor AB Lipidor develops formulation solutions for pharmaceutical substances. www.lipidor.se		NeoDynamics AB NeoDynamics works with a new technology for minimally invasive diagnostics and the treatment of early-stage breast cancer. www.neodynamics.se		NovaSAID AB NovaSAID is developing new drugs for the treatment of inflammatory diseases, such as rheumatoid arthritis and osteoarthritis. www.novasaid.se
Oncopeptides AB Oncopeptides has developed a series of patented oligopeptides for cancer treatment. www.oncopeptides.se		Oss-Q AB The company is developing pioneering implants for bone healing with an initial focus on skull surgery. www.oss-q.com		Pergamum AB Pergamum is a clinical-stage biopharmaceutical company developing state-of-the-art products, based on therapeutic peptides, for local application for treatment of wounds and infections. www.pergamum.com
Pergamum AB Pergamum – is developing antimicrobial peptides against several dermatological indications. www.pergamum.com		Pergamum AB Pergamum develops pharmaceuticals for the treatment of hard-to-heal wounds, including chronic wounds of the skin and mucous membranes. www.pergamum.com		Pergamum AB Pergamum is developing a new therapy to prevent adhesions in connection with surgical procedures. www.pergamum.com
Pharmanest AB Pharmanest develops new treatments against pain in various gynecologic contexts. www.pharmanest.se		Promimic AB Promimic develops and markets a surface treatment that mimics human tissue for implants in bone tissue for such applications as better anchoring of dental prostheses and polymers for back implants. www.promimic.com		ProNoxis AB ProNoxis is developing new small molecules for the treatment of chronic inflammation, such as rheumatoid arthritis, multiple sclerosis and abdominal inflammation. www.pronoxis.se
Umecrine AB Umecrine develops pharmaceuticals against diseases and conditions caused by natural CNS-active sex and stress hormones, known as the GABA steroids. See Umecrine Cognition and Umecrine Mood for more information. www.umecrine.se		Umecrine Cognition AB Umecrine Cognition develops pharmaceuticals against mild Alzheimer’s disease and mild cognitive disorders. www.umecrine.se		Umecrine Mood AB Umecrine Mood is developing pharmaceuticals against premenstrual dysphoric disorder (PMDD) through modulation of the influence of GABA steroids on the brain. www.umecrine.se
XSpray Microparticles AB XSpray Microparticles helps pharmaceutical companies with the formulation of challenging drug substances based on its proprietary, scalable particle manufacturing technology. www.xspray.com

Financial/Passive Investments

BioArctic Neuroscience AB BioArctic Neuroscience develops new treatment methods and diagnostic tools for Alzheimer’s disease and other neurodegenerative diseases. www.bioarctic.se		CytoGuide ApS Cytoguide develops pharmaceuticals that selectively bind receptors on cells in inflamed tissue. www.cytoguide.dk		Laurantis Pharma Oy Laurantis Pharma develops new drugs against atopic dermatitis and cancer. www.pergamum.com
NephroGenex Inc. NephroGenex is developing pharmaceuticals against certain kidney diseases. www.nephrogenex.com